Ironwood Financial llc Sells 885 Shares of Pfizer Inc. (NYSE:PFE)

Ironwood Financial llc cut its position in Pfizer Inc. (NYSE:PFE) by 2.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,472 shares of the biopharmaceutical company’s stock after selling 885 shares during the quarter. Ironwood Financial llc’s holdings in Pfizer were worth $969,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $29,000. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter worth $31,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the second quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday. They issued a “market perform” rating and a $32.00 price target on the stock. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Trading Down 0.9 %

NYSE:PFE traded down $0.28 during mid-day trading on Thursday, hitting $29.39. 2,569,333 shares of the company’s stock were exchanged, compared to its average volume of 37,065,598. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $32.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $166.54 billion, a P/E ratio of -494.33, a PEG ratio of 1.30 and a beta of 0.67. The company has a 50 day simple moving average of $29.04 and a 200-day simple moving average of $28.42.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.72%. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.